F-Star Therapeutics in the spotlight (part III)

FSTX Could See Benefit Of Bristol Myers Squibb's LAG-3 Approval

Bristol Myers Squibb (BMY), the leader in the LAG-3 space has a PDUFA for their LAG-3 antibody relatlimab on Mar 19, 2022. If approved, relatlimab will be the first LAG-3 checkpoint inhibitor on the market, and analysts expect the drug to generate $4B in revenues by 2029 (over $650M/year).

A green light is expected for Bristol’s anti-Lag3 relatlimab give…